European Journal of Clinical Pharmacology

, Volume 32, Issue 1, pp 97–99 | Cite as

Effect of aluminum phosphate on the bioavailability of ranitidine

  • H. Albin
  • G. Vinçon
  • B. Begaud
  • C. Bistue
  • P. Perez
Short Communications

Summary

The effect of aluminum phosphate on the bioavailability of ranitidine has been investigated in 10 young, healthy volunteers. Following a random cross over design, each subject took at a 1 week interval 150 mg ranitidine alone or with 11 g aluminum phosphate. Plasma and urine ranitidine levels were measured by HPLC. The antacid reduced both the maximum plasma ranitidine concentration by 40% and the area under the curve by 30%. Elimination of ranitidine was not changed. The results indicate that aluminum phosphate significantly diminished the bioavailability of ranitidine.

Key words

ranitidine aluminium phosphate antacids bioavailability drug interaction healthy volunteers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albin H, Vinçon G, Bertolaso D, Dangoumau J (1981) Influence du phosphate d'aluminum sur la biodisponibilité de la procaïnamide et du disopyramide. Thérapie 36: 541–546Google Scholar
  2. 2.
    Albin H, Vinçon G, Demotes-Mainard F, Begaud B, Bedjaoui A (1984) Effect of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol 26: 271–273Google Scholar
  3. 3.
    Brazier JL, Tamisier JN, Ambert D, Bannier A (1981) Bioavailability of ketoprofen in man with and without concomitant administration of aluminum phosphate. Eur J Clin Pharmacol 19: 305–307Google Scholar
  4. 4.
    Frislid K, Berstad A (1983) High dose of antacid reduces bioavailability of ranitidine. Br Med J 286: 1358Google Scholar
  5. 5.
    Hurwitz A (1977) Antacid therapy and drug kinetics. Clin Pharmacokinet 2: 269–280Google Scholar
  6. 6.
    Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WH, Smallwood RA (1982) High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J 285: 998Google Scholar
  7. 7.
    Roberts CJC (1984) Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet 9: 211–221Google Scholar
  8. 8.
    Vandenberghe HM, MacLeod SM, Mahon WA, Lebert PA, Soldin SJ (1980) Analysis of ranitidine in serum by high performance liquid chromatography. Ther Drug Monit 2: 379–384Google Scholar
  9. 9.
    Welling PG (1984) Interactions affecting drug absorption. Clin Pharmacokinet 9: 404–434Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • H. Albin
    • 1
  • G. Vinçon
    • 1
  • B. Begaud
    • 1
  • C. Bistue
    • 1
  • P. Perez
    • 1
  1. 1.Department of Clinical PharmacologyHôpital PellegrinBordeauxFrance

Personalised recommendations